TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Stavik, Benedicte ^a,b   Tinholt, Mari ^a,b,c   Sletten, Marit ^a   Skretting, Grethe ^a,b   Sandset, Per Morten ^a,b,c   Iversen, Nina ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Anticoagulant activity; Breast cancer cells; Endothelial cells; Heparin; PI PLC; TF FVIIa; TFPI ; TFPI

Indexed keywords

BLOOD CLOTTING FACTOR 7A; GLYCOSYLPHOSPHATIDYLINOSITOL; HEPARIN; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL LYASE; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR 1ALPHA; TISSUE FACTOR PATHWAY INHIBITOR 1BETA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER ELISA KIT; CELL SURFACE; CONTROLLED STUDY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL MEMBRANE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIIA; FACTOR XA; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LIPOPROTEINS; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THROMBOPLASTIN;

EID: 84872135966     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-5     Document Type: Article

References (42)

1. Structure of the Human Lipoprotein-Associated Coagulation Inhibitor Gene-Intro Exon Gene Organization and Localization of the Gene to Chromosome-2. Girard TJ, Eddy R, Wesselschmidt RL, Macphail LA, Likert KM, Byers MG, Shows TB, Broze GJ, J Biol Chem 1991 266 5036 5041 2002045 (Pubitemid 21909457)
2. Intron Exon Organization of the Human Gene Coding for the Lipoprotein-Associated Coagulation Inhibitor-the Factor-Xa Dependent Inhibitor of the Extrinsic Pathway of Coagulation. Vanderlogt CPE, Reitsma PH, Bertina RM, Biochemistry 1991 30 1571 1577 10.1021/bi00220a018 1993173
3. TFPI beta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene. Chang JY, Monroe DM, Oliver JA, Roberts HR, Thromb Haemost 1999 81 45 49 9974373 (Pubitemid 29041648)
4. Alternatively spliced isoforms of tissue factor pathway inhibitor. Maroney SA, Ellery PE, Mast AE, Thromb Res 2010 125 52 S56 20176395
5. A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. Maroney SA, Cunningham AC, Ferrel J, Hu R, Haberichter S, Mansbach CM, Brodsky RA, Dietzen DJ, Mast AE, J Thromb Haemost 2006 4 1114 1124 10.1111/j.1538-7836.2006.01873.x 16689766
6. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Zhang J, Piro O, Lu L, Broze GJ, Circulation 2003 108 623 627 10.1161/01.CIR.0000078642.45127.7B 12835228 (Pubitemid 36961180)
7. Heparin induces release of extrinsic: Coagulation pathway inhibitor (EPI). Sandset PM, Abildgaard U, Larsen ML, Thromb Res 1988 50 803 813 10.1016/0049-3848(88)90340-4 3413731
8. Cellular Effects of Heparin on the Production and Release of Tissue Factor Pathway Inhibitor in Human Endothelial Cells in Culture. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F, Arterioscler Thromb Vasc Biol 1999 19 2251 2262 10.1161/01.ATV.19.9.2251 10479670 (Pubitemid 29422260)
9. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Hansen JB, Svensson B, Olsen R, Ezban M, Osterud B, Paulssen RH, Thromb Haemost 2000 83 937 943 10896252 (Pubitemid 30411697)
10. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Lindahl AK, Abildgaard U, Staalesen R, Thromb Res 1991 64 155 168 10.1016/0049-3848(91)90115-D 1811336
11. Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin. Valentin S, Østergaard P, Kristensen H, Nordfang O, Blood Coagul Fibrinolysis 1992 3 221 222 10.1097/00001721-199204000-00013 1318759
12. Comparison of cell-surface TFPI alpha and beta. Piro O, Broze GJ, J Thromb Haemost 2005 3 2677 2683 10.1111/j.1538-7836.2005.01636.x 16246254 (Pubitemid 41819795)
13. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, Pendurthi UR, Rao LV, Blood 2004 103 3029 3037 10.1182/blood-2003-10-3417 15070680 (Pubitemid 38451676)
14. Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. Jiang X, Bailly MA, Panetti TS, Cappello M, Konigsberg WH, Bromberg ME, J Thromb Haemost 2004 2 93 101 10.1111/j.1538-7836.2004.00545.x 14717972 (Pubitemid 40185625)
15. Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells. Jiang XF, Zhu SM, Panetti TS, Bromberg ME, Thromb Haemost 2008 100 127 133 18612547 (Pubitemid 351948754)
16. Protease-Activated Receptor-2 Is Essential for Factor VIIa and Xa-Induced Signaling, Migration, and Invasion of Breast Cancer Cells. Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J, Cancer Res 2006 66 307 314 10.1158/0008-5472.CAN-05-1735 16397244 (Pubitemid 43166037)
17. Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Schaffner F, Versteeg HH, Schillert A, Yokota N, Petersen LC, Mueller BM, Ruf W, Blood 2010 116 6106 6113 10.1182/blood-2010-06- 289314 20861457
18. Inhibition of tissue factor signaling suppresses tumor growth. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W, Blood 2008 111 190 199 10.1182/blood-2007-07-101048 17901245
19. Signaling of the Tissue Factor Coagulation Pathway in Angiogenesis and Cancer. Belting M, Ahamed J, Ruf W, Arterioscler Thromb Vasc Biol 2005 25 1545 1550 10.1161/01.ATV.0000171155.05809.bf 15905465 (Pubitemid 41098920)
20. Overexpression of both TFPIalpha and TFPIbeta induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells. Stavik B, Skretting G, Sletten M, Sandset PM, Iversen N, Mol Carcinog 2010 49 951 963 10.1002/mc.20679 20886581
21. Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility. Stavik B, Skretting G, Aasheim HC, Tinholt M, Zernichow L, Sletten M, Sandset P, Iversen N, BMC Canc 2011 11 357 10.1186/1471-2407-11-357
22. TFPI Alpha and Beta Regulate mRNAs and microRNAs Involved in Cancer Biology and in the Immune System in Breast Cancer Cells. Stavik B, Skretting G, Olstad OK, Sletten M, Dehli Vigeland M, Sandset PM, Iversen N, PLoS ONE 2012 7 47184 10.1371/journal.pone.0047184 23071754
23. Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Kurer MA, Mol Biol Rep 2007 34 221 224 10.1007/s11033-006-9036-4 17180732 (Pubitemid 47624283)
24. Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Sierko E, Wojtukiewicz MZ, Zimnoch L, Kisiel W, Thromb Haemost 2010 103 198 204 20062932
25. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Iversen N, Lindahl AK, Abildgaard U, Br J Haematol 1998 102 889 895 10.1046/j.1365-2141.1998.00875.x 9734635 (Pubitemid 28410516)
26. Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. Iversen N, Lindahl AK, Abildgaard U, Thromb Res 2002 105 33 36 10.1016/S0049-3848(01)00404-2 11864704 (Pubitemid 34178305)
27. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. Canc Cell 2006 10 515 527 10.1016/j.ccr.2006.10.008 (Pubitemid 44854747)
28. Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, et al. PLoS One 2009 4 6146 10.1371/journal.pone.0006146 19582160
29. TFPb is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes. Girard TJ, Tuley E, Broze GJ, Blood 2012 119 1256 1262 10.1182/blood-2011-10-388512 22144186
30. Detection of the Three Kunitz-Type Single Domains of Membrane-Bound Tissue Factor Pathway Inhibitor (TFPI) by Flow Cytometry. Tiemann C, Brinkmann T, Kleesiek K, Clin Chem Lab Med 1997 35 855 860
31. ECV304 (endothelial) is really T24 (bladder carcinoma): Cell line cross-contamination at source. Dirks W, MacLeod R, Drexler H, In Vitro Cell Dev Biol Anim 1999 35 558 559 10.1007/s11626-999-0091-8 10614862 (Pubitemid 30007650)
32. Further insight into the heparin-releasable and glycosylphosphatidylinositol-lipid-anchored forms of tissue factor pathway inhibitor. Ellery PER, Hardy K, Oostryck R, Adams MJ, Clin Appl Thromb Hemost 2008 14 267 278 10.1177/1076029607304239 18160611 (Pubitemid 351871936)
33. Characterization of the association of tissue factor pathway inhibitor with human placenta. Mast AE, Acharya N, Malecha MJ, Hall CL, Dietzen DJ, Arterioscler Thromb Vasc Biol 2002 22 2099 2104 10.1161/01.ATV.0000042456.84190. F0 12482841 (Pubitemid 36025221)
34. Human Ryudocan from Endothelium-like Cells Binds Basic Fibroblast Growth Factor, Midkine, and Tissue Factor Pathway Inhibitor. Kojima T, Katsumi A, Yamazaki T, Muramatsu T, Nagasaka T, Ohsumi K, Saito H, J Biol Chem 1996 271 5914 5920 10.1074/jbc.271.10.5914 8621465 (Pubitemid 26084457)
35. Differential expression of human tissue factor in normal mammary epithelial cells and in carcinomas. Chen Z, Sager R, Mol Med 1995 1 153 160 8529094
36. Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Jiang X, Guo YL, Bromberg ME, Thromb Haemost 2006 96 196 201 16894464 (Pubitemid 44219388)
37. CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Ngo CV, Picha K, McCabe F, Millar H, Tawadros R, Tam SH, Nakada MT, Anderson GM, Int J Cancer 2007 120 1261 1267 10.1002/ijc.22426 17192924
38. Differentiation state and invasiveness of human breast cancer cell lines. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP, Breast Canc Res Treat 1994 31 325 335 10.1007/BF00666165 (Pubitemid 24323473)
39. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, et al. J Cell Physiol 1992 150 534 544 10.1002/jcp.1041500314 1537883
40. Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. Tong D, Czerwenka K, Sedlak J, Schneeberger C, Schiebel I, Concin N, Leodolter S, Zeillinger R, Breast Canc Res Treat 1999 56 91 97 10.1023/A:1006262501062 (Pubitemid 29435818)
41. In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line. Hoffmeyer MR, Wall KM, Dharmawardhane SF, Canc Cell Int 2005 5 11 10.1186/1475-2867-5-11 (Pubitemid 41460755)
42. Role of Epidermal Growth Factor Receptor and STAT-3 Activation in Autonomous Proliferation of SUM-102PT Human Breast Cancer Cells. Sartor CI, Dziubinski ML, Yu CL, Jove R, Ethier SP, Cancer Res 1997 57 978 987 9041204 (Pubitemid 27098027)